PACE (Pathways to Antimicrobial Clinical Efficacy) has launched its third [...]
Deal gives Shionogi access to BioVersys’ BV500 program targeting serious [...]
PACE (Pathways to Antimicrobial Clinical Efficacy) has launched its third [...]
Deal gives Shionogi access to BioVersys’ BV500 program targeting serious [...]